Lansoprazole USP 30 mg Capsule.
Healing and long term management of gastroesophageal reflux disease. Healing and maintenance therapy for patients with duodenal ulcer. Relief of reflux-like symptoms (eg. Heartburn) and/or ulcer-like symptoms (eg. upper epigastric pain) associated with acid-related dyspepsia. Healing of benign gastric ulcer. Lansec is also effective in patients with benign peptic lesions, including reflux oesophagitis, unresponsive to H2 receptor antagonists. Eradication of H.pylori from the upper gastro-intestinal tract in patients with duodenal ulcer or gastritis when used in combination with appropriate antibiotics.
Lansoprazole USP 30 mg Capsule.
Healing and long term management of gastroesophageal reflux disease. Healing and maintenance therapy for patients with duodenal ulcer. Relief of reflux-like symptoms (eg. Heartburn) and/or ulcer-like symptoms (eg. upper epigastric pain) associated with acid-related dyspepsia. Healing of benign gastric ulcer. Lansec is also effective in patients with benign peptic lesions, including reflux oesophagitis, unresponsive to H2 receptor antagonists. Eradication of H.pylori from the upper gastro-intestinal tract in patients with duodenal ulcer or gastritis when used in combination with appropriate antibiotics.
Drug International Limited was incorporated under the Registrar of Joint Stock Companies in 1974 as a Private Limited Company. The company commenced formulation and production in 1983 and emerged as a pioneer in Bangladesh for adding a state of the art oral solid dosage plant. Since inception, Drug International Limited's primary objective has been to meet guidelines provided by major global regulatory bodies such as the World Health Organization Good Manufacturing Practices (WHO cGMP) guidelines.